Abstract
FOXM1 (forkhead box protein M1) is a critical proliferation-associated transcription factor that is widely spatiotemporally expressed during the cell cycle. It is closely involved with the processes of cell proliferation, self-renewal, and tumorigenesis. In most human cancers, FOXM1 is overexpressed, and this indicates a poor prognosis for cancer patients. FOXM1 maintains cancer hallmarks by regulating the expression of target genes at the transcriptional level. Due to its potential role as molecular target in cancer therapy, FOXM1 was named the Molecule of the Year in 2010. However, the mechanism of FOXM1 dysregulation remains indistinct. A comprehensive understanding of FOXM1 regulation will provide novel insight for cancer and other diseases in which FOXM1 plays a major role. Here, we summarize the transcriptional regulation, post-transcriptional regulation and post-translational modifications of FOXM1, which will provide extremely important implications for novel strategies targeting FOXM1.
Similar content being viewed by others
Background
Forkhead box M1 (FOXM1), previously named HNF-3, HFH-11 or Trident, is a transcription factor of the Forkhead box (Fox) protein superfamily which is defined by a conserved winged helix DNA-binding domain1 [1]. The human FOXM1 gene consists of 10 exons, of which exons Va and VIIa can be alternatively spliced [2]. In the past, VIIa was treated as a repressor until a novel isoform (FOXM1d) that could promote the epithelial–mesenchymal transition (EMT) and metastasis by activating ROCKs in colorectal cancer was identified [3, 4]. Accordingly, there are four isoforms of human FOXM1 identified to date (Fig. 1a). FOXM1a contains both exons Va and VIIa and lacks transactivation activity, while the rest of the three, FOXM1b (which contains neither exon Va nor VIIa), FOXM1c (no VIIa) and FOXM1d (no Va) are transcriptionally active. The FOXM1 protein contains a conserved forkhead DNA-binding domain (DBD), an N-terminal repressor domain (NRD), and a C-terminal transactivation domain (TAD). The transactivation activity of TAD can be suppressed by direct interaction with the NRD [5, 6]. In addition, murine FOXM1 splice variants display the same DNA-binding specificity as human FOXM1 and bind to DNA-binding sites with the consensus sequence 5′-A-C/T-AAA-C/ T-AA-3’ [7]. The study of murine FOXM1 may also be applied to human FOXM1. For example, it has been demonstrated that Gli1 regulates FOXM1 in murine stem cells [8]. In human basal cell carcinomas and colorectal cancer cells, FOXM1 is also a direct target of Gli1 [9, 10]. This may be due to the evolutionary conservation between the DNA binding domain of both human and murine FOXM1, suggesting the FOXM1 of the two species may share target genes. As such, investigating the regulation of murine FOXM1 may provide significant implications into the dysregulation of human FOXM1. Furthermore, a mouse model is a suitable experimental model for the development of novel FOXM1 inhibitors.
FOXM1 is detected primarily in progenitor and regenerating tissues, as well as tumor cells, which are all highly proliferative [11]. As a classic proliferation-associated transcription factor, FOXM1 directly or indirectly activates the expression of target genes at the transcriptional level and exhibits a spatiotemporal pattern whose dysregulation is involved in almost all hallmarks of tumor cells [3, 12]. Increased expression of FOXM1 is observed in a variety of human cancers, such as ovarian cancer, breast cancer, prostate cancer, hepatoma, angiosarcoma, colorectal cancer, melanoma, lung cancer, and gastric cancer [13,14,15,16,17,18,19,20,21], which is consistent with the results obtained from the TCGA database (Fig. 2). Inhibition of FOXM1 in cancer cells leads to decreased cell proliferation and migration, metastasis, angiogenesis, EMT, and drug resistance [22,23,24,25,26]. Furthermore, a recent meta-analysis revealed that elevated FOXM1 expression is related to poor prognosis in most solid tumors [27], which is also further confirmed by the TCGA database (Fig. 3) [28]. These results clearly showed the important role of FOXM1 in tumorigenesis and cancer development. Therefore, FOXM1 has been identified as a potential therapeutic target for the treatment of cancers. Although a few drugs and inhibitors have been shown to be effective at inhibiting the activity of FOXM1 in vitro, they’ve yet to pass successfully into clinical use [29]. This is likely due in major part to the poor current understanding of the regulation of FOXM1. Hence, a comprehensive review of FOXM1 regulation will thus contribute to the extensive effort and research into the gene as a therapeutic target for a number of FOXM1-dependent conditions, such as the cancers mentioned previously.
In this review, we provide an overview of how FOXM1 is regulated and focus on the transcriptional, post-transcriptional, post-translational, and protein-protein/RNA interaction levels. Though many biomolecules regulate the expression of FOXM1, we emphasize the biomolecules that directly interact with or modify the promoter, RNA, or protein of FOXM1. At the same time, we will discuss briefly the pharmacological inhibition of FOXM1.
Transcriptional regulation of FOXM1
The core promoter regions of the FOXM1 gene contain several classic regulatory elements, such as E-boxes, and other cis-acting elements that can function as responsive elements to other transcription factors. Here, we mainly discuss the transcription factors that directly bind to the promoter regions (which are verified by electrophoretic mobility shift assays and/or chromatin immunoprecipitation assays) (Fig. 1b).
Most responsive elements are located adjacent to FOXM1’s transcriptional start sites, though the furthest element is found approximately 2000 bp away. More than 75% of these binding sites act as cis-activation elements, but they do not all function through the same basic mechanisms. For example, glioma-associated oncogene homolog 1 (Gli1), CCCTC-binding factor (CTCF), cAMP responsive element-binding protein (CREB), signal transducer and activator of transcription 3 (STAT3), and E2F interact directly with their binding sites and upregulate FOXM1 expression [9, 30,31,32,74].
FOXM1 ubiquitination is also linked to SUMOylation. For example, RNF168 can modulate DNA-damage response (DDR) by promoting protein ubiquitination. In breast cancer treated with epirubicin, FOXM1 is modified through SUMOylation, which leads to its ubiquitination and degradation by RNF168 E3 ubiquitin ligase [75].
In contrast, deubiquitinating enzymes (DUBs) can remove the poly-ubiquitin chains on FOXM1 protein. For instance, in epirubicin-resistant breast cancer and in ovarian cancer, OTUB1 catalyzes the cleavage of the K48-specific ubiquitin linkage from FOXM1, which promotes cancer progression via facilitating cell proliferation and drug resistance [76, 77].
SUMOylation
Small Ubiquitin-like Modifier (SUMO) proteins are small proteins that are covalently attached to other proteins and modify their function. In mammals, there are four SUMO isoforms, SUMO-1, SUMO-2, SUMO-3, and SUMO-4. SUMOylation is an important PTM of FOXM1 that regulates its activity, stability, and other PTMs. The functions of FOXM1 SUMOylation are diverse and may regulate its activity in an isoform-specific manner.
Multiple sites of FOXM1 are modified by SUMO-2, and this modification peaks in the M phase, which is consistent with its phosphorylation. This modification blocks the dimerization and relieves the auto-repression of FOXM1, thereby increasing its transcriptional activity [78]. Another SUMOylation of FOXM1 at K463 by SUMO-1 is also required for its transcriptional activity [79].
In contrast, SUMOlyation of FOXM1 at different sites may inhibit its activity. For instance, FOXM1c is modified by SUMO-1 at multiple sites, which promotes the cytoplasmic translocation of FOXM1c and enhances APC/Cdh1-dependent ubiquitin-mediated degradation. This modification subsequently attenuates the transcriptional activity of FOXM1c [80]. This phenomenon has been confirmed with another FOXM1 isoform-FOXM1b [81].
Other PTMs of FOXM1
FOXM1 is also regulated by acetyltransferases and methyltransferases. For instance, FOXM1 can be acetylated by p300/CBP at lysines K63, K422, K440, K603 and K614, which enhances its transcriptional activity by promoting its DNA binding affinity, protein stability, and phosphorylation sensitivity [103]. Furthermore, latest reports revealed that FOXM1 modulates atherosclerosis by inducing macrophage proliferation [104]. However, little is known about the possible role of FOXM1 in tumor microenvironment. Interestingly, FOXM1 (362–370) (YLVPIQFPV), FOXM1(373–382) (SLVLQPSVKV), and FOXM1(640–649) (GLMDLSTTPL) peptides primed HLA-A2-restricted cytotoxic T lymphocytes (CTLs) in the HLA-A2 transgenic mice, suggesting that FOXM1 may be a suitable target for immunotherapy against cancers. However, the HLAA2-restricted epitopes of FOXM1 identified need to be further clinically tested [105]. As the important role of FOXM1 in cell proliferation and determination of cell fate, more study is needed to reveal the possible role of FOXM1 in the tumor infiltrating immune cells.
Conclusions and future perspectives
FOXM1 is a crucial regulator of many biological processes and tissues, and dysregulation of FOXM1 can significantly contribute to tumorigenesis and cancer progression. For its potential as a target for cancer therapies, FOXM1 was named the Molecule of the Year in 2010 [106]. Over the past few decades, understanding of the regulation and function of FOXM1 has rapidly increased, providing new insights into the roles of this transcription factor in cancer and other diseases. At the same time, some small molecule inhibitors that target FOXM1 have promising potential as drugs for cancer treatment [107, 108]. However, there are important challenges that limit the translation of promising drugs into clinical practice. Before the entry of FOXM1 inhibitors into clinical trials, more thorough preclinical studies on their anti-tumor efficacy are still needed. In addition, the toxicity of the above drugs should also be fully evaluated. It is not quite clear how the interaction and isoforms switch between FOXM1a and FOXM1b or FOXM1c or FOXM1d. It also remains unclear how the isoforms of FOXM1 interact and what role they may play in the regulation of FOXM1, in disease progression, or in response to relevant therapeutic strategies. Importantly, although the crystal structure of the FOXM1 DNA-recognition domain has been fully identified [7], it is vital that the complete structure of the FOXM1 protein be elucidated. This will be of utmost importance for the discovery of novel FOXM1 inhibitors.
In this review, we have summarized many of the activators and repressors that directly interact with or modify FOXM1 at multiple levels and drew the FOXM1-interaction network diagram (Fig. 4). The comprehensive understanding of the regulation of FOXM1 will provide a basis for further investigation, which may provide new potential therapeutic strategies.
Abbreviations
- APC/C:
-
Anaphase-promoting complex-cyclosome
- AURKA:
-
Aurora kinase A
- CCAT2:
-
Colon cancer-associated transcript 2
- CDC25A:
-
Cell division cycle 25A
- ceRNAs:
-
Competing endogenous RNAs
- Chk2:
-
Checkpoint kinase 2
- CRC:
-
Colorectal cancer
- CREB:
-
cAMP responsive element-binding protein
- CTCF:
-
CCCTC-binding factor
- DBD:
-
Forkhead DNA-binding domain
- EMT:
-
Epithelial-mesenchymal transition
- ERE:
-
Estrogen-response element
- FBXW7:
-
F-box/WD repeat-containing protein 7
- FDI-6:
-
A small molecule compound
- FOXM1 Apt:
-
FOXM1-specific single stranded DNA aptamer
- FOXM1:
-
Human Forkhead Box M1
- GBC:
-
Gallbladder cancer
- Gli1:
-
Glioma-associated oncogene homolog 1
- GSC:
-
Glioma stem-like cell
- HCC:
-
Hepatocellular carcinoma
- HDAC:
-
Histone deacetylases
- HIF-1:
-
Hypoxia-inducible factor 1
- HSF1:
-
Heat shock factor 1
- lncRNAs:
-
Long non-coding RNAs
- LXRa:
-
Liver X receptor a
- MAPK:
-
Mitogen-activated Protein Kinase
- MELK:
-
Maternal embryonic leucine-zipper kinase
- miRNAs:
-
MicroRNAs
- MnSOD:
-
Manganese-dependent superoxide dismutase
- MREs:
-
Response elements
- MTDH:
-
Metadherin/astrocyte elevated gene-1
- ncRNA:
-
Non-coding RNA
- NPM:
-
Nucleophosmin
- NRD:
-
N-terminal repressor domain
- p19ARF :
-
19-kD alternative reading frame (ARF) protein
- Peptide 9R-P201:
-
A peptidomimetics from the phage random library
- RCM-1:
-
Robert Costa Memorial drug–1
- SETD3:
-
SET domain-containing protein
- STAT3:
-
Signal transducer and activator of transcription 3
- SUMO:
-
Small Ubiquitin-like Modifier
- TAD:
-
C-terminal transactivation domain
- TNF-α:
-
Tumor necrosis factor alpha
- Twist1:
-
Twist-related protein 1
References
Clark KL, Halay ED, Lai E, Burley SK. Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature. 1993;364:412. https://doi.org/10.1038/364412a0.
Korver W, Roose J, Heinen K, Weghuis DO, de Bruijn D, van Kessel AG, Clevers H. The human TRIDENT/HFH-11/FKHL16 gene: structure, localization, and promoter characterization. Genomics. 1997;46:435–42. https://doi.org/10.1006/geno.1997.5065.
Zona S, Bella L, Burton MJ, Nestal de Moraes G, Lam EW-F. FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance. Biochim Biophys Acta. 2014;1839:1316–22. https://doi.org/10.1016/j.bbagrm.2014.09.016.
Zhang X, Zhang L, Du Y, Zheng H, Zhang P, Sun Y, Wang Y, Chen J, Ding P, Wang N, Yang C, Huang T, Yao X, Qiao Q, Gu H, Cai G, Cai S, Zhou X, Hu W. A novel FOXM1 isoform, FOXM1D, promotes epithelial-mesenchymal transition and metastasis through ROCKs activation in colorectal cancer. Oncogene. 2017;36:807–19. https://doi.org/10.1038/onc.2016.249.
Park HJ, Wang Z, Costa RH, Tyner A, Lau LF, Raychaudhuri P. An N-terminal inhibitory domain modulates activity of FoxM1 during cell cycle. Oncogene. 2008;27:1696–704. https://doi.org/10.1038/sj.onc.1210814.
Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM, Zhai H, Vidal M, Gygi SP, Braun P, Sicinski P. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell. 2011;20:620–34. https://doi.org/10.1016/j.ccr.2011.10.001.
Littler DR, Alvarezfernández M, Stein A, Hibbert RG, Heidebrecht T, Aloy P, Medema RH, Perrakis A. Structure of the FoxM1 DNA-recognition domain bound to a promoter sequence. Nucleic Acids Res. 2010;38:4527–38. https://doi.org/10.1093/nar/gkq194.
Besharat ZM, Abballe L, Cicconardi F, Bhutkar A, Grassi L, Le Pera L, Moretti M, Chinappi M, D’Andrea D, Mastronuzzi A. Foxm1 controls a pro-stemness microRNA network in neural stem cells. Sci Rep. 2018;8 https://doi.org/10.1038/s41598-018-21876-y.
Wang D, Hu G, Du Y, Zhang C, Lu Q, Lv N, Luo S. Aberrant activation of hedgehog signaling promotes cell proliferation via the transcriptional activation of forkhead box M1 in colorectal cancer cells. J Exp Clin Cancer Res. 2017;36:23. https://doi.org/10.1186/s13046-017-0491-7.
Teh M-T, Wong S-T, Neill GW, Ghali LR, Philpott MP, Quinn AG. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res. 2002;62:4773–80.
Nandi D, Cheema PS, Jaiswal N, Nag A. FoxM1: repurposing an oncogene as a biomarker. Semin Cancer Biol. 2017; https://doi.org/10.1016/j.semcancer.2017.08.009.
Wierstra I. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv Cancer Res. 2013;119:191–419. https://doi.org/10.1016/B978-0-12-407190-2.00016-2.
Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D’Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. J Exp Clin Cancer Res. 2017;36:63. https://doi.org/10.1186/s13046-017-0536-y.
Abdeljaoued S, Bettaieb I, Nasri M, Adouni O, Goucha A, El Amine O, Boussen H, Rahal K, Gamoudi A. Overexpression of FOXM1 is a potential prognostic marker in male breast Cancer. Oncol Res Treat. 2017;40:167–72. https://doi.org/10.1159/000458156.
Liu Y, Liu Y, Yuan B, Yin L, Peng Y, Yu X, Zhou W, Gong Z, Liu J, He L, Li X. FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription. Oncotarget. 2017;8:17027–37. https://doi.org/10.18632/oncotarget.15224.
Egawa M, Yoshida Y, Ogura S, Kurahashi T, Kizu T, Furuta K, Kamada Y, Chatani N, Hamano M, Kiso S, Hikita H, Tatsumi T, Eguchi H, Nagano H, Doki Y, Mori M, Takehara T. Increased expression of Forkhead box M1 transcription factor is associated with clinicopathological features and confers a poor prognosis in human hepatocellular carcinoma. Hepatol Res. 2017;47:1196–205. https://doi.org/10.1111/hepr.12854.
Ito T, Kohashi K, Yamada Y, Iwasaki T, Maekawa A, Kuda M, Hoshina D, Abe R, Furue M, Oda Y. Prognostic significance of Forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in Angiosarcoma. J Cancer. 2016;7:823–30. https://doi.org/10.7150/jca.14461.
Zhang H, Zhong H, Li L, Ji W, Zhang X. Overexpressed transcription factor FOXM1 contributes to the progression of colorectal cancer. Mol Med Rep. 2016;13:2696–700. https://doi.org/10.3892/mmr.2016.4875.
Ito T, Kohashi K, Yamada Y, Maekawa A, Kuda M, Furue M, Oda Y. Prognostic significance of forkhead box M1 (FoxM1) expression and antitumour effect of FoxM1 inhibition in melanoma. Histopathology. 2016;69:63–71. https://doi.org/10.1111/his.12909.
Kong F-F, Qu Z-Q, Yuan H-H, Wang J-Y, Zhao M, Guo Y-H, Shi J, Gong X-D, Zhu Y-L, Liu F, Zhang W-Y, Jiang B. Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer. Oncol Rep. 2014;31:2660–8. https://doi.org/10.3892/or.2014.3129.
Okada K, Fujiwara Y, Takahashi T, Nakamura Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Mori M, Doki Y. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer. Ann Surg Oncol. 2013;20:1035–43. https://doi.org/10.1245/s10434-012-2680-0.
Zhong S, Zhou A, Qi F, Li Z, Yu Z, Lu Y, Liu X. Downregulating forkhead box M1 inhibits proliferation by inhibiting autophagy in the sw480 cell line. Biomed Rep. 2017;7:47–50. https://doi.org/10.3892/br.2017.915.
Zhang J, Niu Y, Huang C. Role of FoxM1 in the progression and epithelial to mesenchymal transition of gastrointestinal Cancer. Recent Pat Anticancer Drug Discov. 2017;12:247–59. https://doi.org/10.2174/1574892812666170424144352.
Wang K, Zhu X, Zhang K, Zhu L, Zhou F. FoxM1 inhibition enhances chemosensitivity of docetaxel-resistant A549 cells to docetaxel via activation of JNK/mitochondrial pathway. Acta Biochim Biophys Sin Shanghai. 2016;48:804–9. https://doi.org/10.1093/abbs/gmw072.
Yu C, Chen L, Yie L, Wei L, Wen T, Liu Y, Chen H. Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelialto-mesenchymal transition pathway. Oncol Rep. 2015;33:2402–10. https://doi.org/10.3892/or.2015.3834.
Jiang L, Wang P, Chen L, Chen H. Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells. Int J Clin Exp Pathol. 2014;7:5450–60.
Li L, Wu D, Yu Q, Li L, Wu P. Prognostic value of FOXM1 in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8:32298–308. https://doi.org/10.18632/oncotarget.15764.
Chandrashekar DS, Bashel B, Sah B, Creighton CJ, Poncerodriguez I, Bvsk C, Varambally S. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649–58. https://doi.org/10.1016/j.neo.2017.05.002.
Koo C-Y, Muir KW, Lam EW-F. FOXM1: from cancer initiation to progression and treatment. Biochim Biophys Acta. 2012;1819:28–37. https://doi.org/10.1016/j.bbagrm.2011.09.004.
Zhang B, Zhang Y, Zou X, Chan AWH, Zhang R, Lee TK-W, Liu H, Lau EY-T, Ho NP-Y, Lai PBS, Cheung Y-S, K.-F. To, Wong HK, Choy KW, Keng VW, Chow LMC, Chan KKY, Cheng AS, Ko BCB. CTCF-FOXM1 axis regulates tumor growth and metastasis in hepatocellular carcinoma. J Pathol. 2017; https://doi.org/10.1002/path.4976.
Chen P-M, Wu T-C, Shieh S-H, Wu Y-H, Li M-C, Sheu G-T, Cheng Y-W, Chen C-Y, Lee H. MnSOD promotes tumor invasion via upregulation of FoxM1-MMP2 axis and related with poor survival and relapse in lung adenocarcinomas. Mol Cancer Res. 2013;11:261–71. https://doi.org/10.1158/1541-7786.MCR-12-0527.
Mencalha AL, Binato R, Ferreira GM, Du Rocher B, Abdelhay E. Forkhead box M1 (FoxM1) gene is a new STAT3 transcriptional factor target and is essential for proliferation, survival and DNA repair of K562 cell line. PLoS One. 2012;7:e48160. https://doi.org/10.1371/journal.pone.0048160.
**a L, Huang W, Tian D, Zhu H, Zhang Y, Hu H, Fan D, Nie Y, Wu K. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma. J Hepatol. 2012;57:600–12. https://doi.org/10.1016/j.jhep.2012.04.020.
Millour J, de Olano N, Horimoto Y, Monteiro LJ, Langer JK, Aligue R, Hajji N, Lam EWF. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol Cancer Ther. 2011;10:1046–58. https://doi.org/10.1158/1535-7163.MCT-11-0024.
Qian J, Luo Y, Gu X, Zhan W, Wang X. Twist1 promotes gastric cancer cell proliferation through up-regulation of FoxM1. PLoS One. 2013;8:e77625. https://doi.org/10.1371/journal.pone.0077625.
**a L-M, Huang W-J, Wang B, Liu M, Zhang Q, Yan W, Zhu Q, Luo M, Zhou Z-Z, Tian D-A. Transcriptional up-regulation of FoxM1 in response to hypoxia is mediated by HIF-1. J Cell Biochem. 2009;106:247–56. https://doi.org/10.1002/jcb.21996.
**a L, Mo P, Huang W, Zhang L, Wang Y, Zhu H, Tian D, Liu J, Chen Z, Zhang Y, Chen Z, Hu H, Fan D, Nie Y, Wu K. The TNF-alpha/ROS/HIF-1-induced upregulation of FoxMI expression promotes HCC proliferation and resistance to apoptosis. Carcinogenesis. 2012;33:2250–9. https://doi.org/10.1093/carcin/bgs249.
Dai B, Gong A, **g Z, Aldape KD, Kang S-H, Sawaya R, Huang S. Forkhead box M1 is regulated by heat shock factor 1 and promotes glioma cells survival under heat shock stress. J Biol Chem. 2013;288:1634–42. https://doi.org/10.1074/jbc.M112.379362.
Hu C, Liu D, Zhang Y, Lou G, Huang G, Chen B, Shen X, Gao M, Gong W, Zhou P, Dai S, Zeng Y, He F. LXRalpha-mediated downregulation of FOXM1 suppresses the proliferation of hepatocellular carcinoma cells. Oncogene. 2014;33:2888–97. https://doi.org/10.1038/onc.2013.250.
Barsotti AM, Prives C. Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene. 2009;28:4295–305. https://doi.org/10.1038/onc.2009.282.
Kurinna S, Stratton SA, Coban Z, Schumacher JM, Grompe M, Duncan AW, Barton MC. p53 regulates a mitotic transcription program and determines ploidy in normal mouse liver. Hepatology. 2013;57(2013):2004. https://doi.org/10.1002/hep.26233.
Millour J, Constantinidou D, Stavropoulou AV, Wilson MSC, Myatt SS, Kwok JM-M, Sivanandan K, Coombes RC, Medema RH, Hartman J, Lykkesfeldt AE, Lam EW-F. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene. 2010;29:2983–95. https://doi.org/10.1038/onc.2010.47.
Horimoto Y, Hartman J, Millour J, Pollock S, Olmos Y, Ho K-K, Coombes RC, Poutanen M, Makela SI, El-Bahrawy M, Speirs V, Lam EW-F. ERbeta1 represses FOXM1 expression through targeting ERalpha to control cell proliferation in breast cancer. Am J Pathol. 2011;179:1148–56. https://doi.org/10.1016/j.ajpath.2011.05.052.
Blanco-Bose WE, Murphy MJ, Ehninger A, Offner S, Dubey C, Huang W, Moore DD, Trumpp A. C-Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia. Hepatology. 2008;48:1302–11. https://doi.org/10.1002/hep.22475.
Delpuech O, Griffiths B, East P, Essafi A, Lam EW-F, Burgering B, Downward J, Schulze A. Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression. Mol Cell Biol. 2007;27:4917–30. https://doi.org/10.1128/MCB.01789-06.
Halasi M, Gartel AL. A novel mode of FoxM1 regulation: positive auto-regulatory loop. Cell Cycle. 2009;8:1966–7. https://doi.org/10.4161/cc.8.12.8708.
Cheng X-H, Black M, Ustiyan V, Le T, Fulford L, Sridharan A, Medvedovic M, Kalinichenko VV, Whitsett JA, Kalin TV. SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene. PLoS Genet. 2014;10:e1004656. https://doi.org/10.1371/journal.pgen.1004656.
Gartel AL. Targeting FOXM1 auto-regulation in cancer. Cancer Biol Ther. 2015;16:185–6. https://doi.org/10.4161/15384047.2014.987566.
Yang N, Wang C, Wang Z, Zona S, Lin S-X, Wang X, Yan M, Zheng F-M, Li S-S, Xu B, Bella L, Yong J-S, Lam EW-F, Liu Q. FOXM1 recruits nuclear aurora kinase a to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells. Oncogene. 2017;36:3428–40. https://doi.org/10.1038/onc.2016.490.
**e X, Lu J, Kulbokas EJ, Golub TR, Mootha V, Lindblad-Toh K, Lander ES, Kellis M. Systematic discovery of regulatory motifs in human promoters and 3’ UTRs by comparison of several mammals. Nature. 2005;434:338–45. https://doi.org/10.1038/nature03441.
Xu Z, Yan Y, Qian L, Gong Z. Long non-coding RNAs act as regulators of cell autophagy in diseases (Review). Oncol Rep. 2017;37:1359–66. https://doi.org/10.3892/or.2017.5416.
Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152:1298–307. https://doi.org/10.1016/j.cell.2013.02.012.
Yamamura S, Imai-Sumida M, Tanaka Y, Dahiya R. Interaction and cross-talk between non-coding RNAs. Cell Mol Life Sci. 2017; https://doi.org/10.1007/s00018-017-2626-6.
Wang J-M, Ju B-H, Pan C-J, Gu Y, Li M-Q, Sun L, Xu Y-Y, Yin L-R. MiR-214 inhibits cell migration, invasion and promotes the drug sensitivity in human cervical cancer by targeting FOXM1. Am J Transl Res. 2017;9:3541–57.
Liu X, **e T, Mao X, Xue L, Chu X, Chen L. MicroRNA-149 increases the sensitivity of colorectal Cancer cells to 5-fluorouracil by targeting Forkhead box transcription factor FOXM1. Cell Physiol Biochem. 2016;39:617–29. https://doi.org/10.1159/000445653.
Li X-R, Chu H-J, Lv T, Wang L, Kong S-F, Dai S-Z. miR-342-3p suppresses proliferation, migration and invasion by targeting FOXM1 in human cervical cancer. FEBS Lett. 2014;588:3298–307. https://doi.org/10.1016/j.febslet.2014.07.020.
Wang S-H, Ma F, Tang Z-H, Wu X-C, Cai Q, Zhang M-D, Weng M-Z, Zhou D, Wang J-D, Quan Z-W. Long non-coding RNA H19 regulates FOXM1 expression by competitively binding endogenous miR-342-3p in gallbladder cancer. J Exp Clin Cancer Res. 2016;35:160. https://doi.org/10.1186/s13046-016-0436-6.
Chen F, Bai G, Li Y, Feng Y, Wang L. A positive feedback loop of long noncoding RNA CCAT2 and FOXM1 promotes hepatocellular carcinoma growth. Am J Cancer Res. 2017;7:1423–34.
Chen Y-J, Dominguez-Brauer C, Wang Z, Asara JM, Costa RH, Tyner AL, Lau LF, Raychaudhuri P. A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1. J Biol Chem. 2009;284:30695–707. https://doi.org/10.1074/jbc.M109.007997.
Ma RYM, Tong THK, Cheung AMS, Tsang ACC, Leung WY, Yao K-M. Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. J Cell Sci. 2005;118:795–806. https://doi.org/10.1242/jcs.01657.
Alvarez-Fernandez M, Halim VA, Aprelia M, Laoukili J, Mohammed S, Medema RH. Protein phosphatase 2A (B55alpha) prevents premature activation of forkhead transcription factor FoxM1 by antagonizing cyclin a/cyclin-dependent kinase-mediated phosphorylation. J Biol Chem. 2011;286:33029–36. https://doi.org/10.1074/jbc.M111.253724.
Luscher-Firzlaff JM, Lilischkis R, Luscher B. Regulation of the transcription factor FOXM1c by cyclin E/CDK2. FEBS Lett. 2006;580:1716–22. https://doi.org/10.1016/j.febslet.2006.02.021.
Laoukili J, Alvarez M, Meijer LAT, Stahl M, Mohammed S, Kleij L, Heck AJR, Medema RH. Activation of FoxM1 during G2 requires cyclin a/Cdk-dependent relief of autorepression by the FoxM1 N-terminal domain. Mol Cell Biol. 2008;28:3076–87. https://doi.org/10.1128/MCB.01710-07.
Fu Z, Malureanu L, Huang J, Wang W, Li H, van Deursen JM, Tindall DJ, Chen J. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol. 2008;10:1076–82. https://doi.org/10.1038/ncb1767.
Major ML, Lepe R, Costa RH. Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators. Mol Cell Biol. 2004;24:2649–61.
Tan Y, Raychaudhuri P, Costa RH. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol. 2007;27:1007–16. https://doi.org/10.1128/MCB.01068-06.
Chen Y, Li Y, Xue J, Gong A, Yu G, Zhou A, Lin K, Zhang S, Zhang N, Gottardi CJ, Huang S. Wnt-induced deubiquitination FoxM1 ensures nucleus beta-catenin transactivation. EMBO J. 2016;35:668–84. https://doi.org/10.15252/embj.201592810.
Zhang J, Yuan C, Wu J, Elsayed Z, Fu Z. Polo-like kinase 1-mediated phosphorylation of Forkhead box protein M1b antagonizes its SUMOylation and facilitates its mitotic function. J Biol Chem. 2015;290:3708–19. https://doi.org/10.1074/jbc.M114.634386.
Newton K, Matsumoto ML, Wertz IE, Kirkpatrick DS, Lill JR, Tan J, Dugger D, Gordon N, Sidhu SS, Fellouse FA, Komuves L, French DM, Ferrando RE, Lam C, Compaan D, Yu C, Bosanac I, Hymowitz SG, Kelley RF, Dixit VM. Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell. 2008;134:668–78. https://doi.org/10.1016/j.cell.2008.07.039.
Pfleger CM, Kirschner MW. The KEN box: an APC recognition signal distinct from the D box targeted by Cdh1. Genes Dev. 2000;14:655–65. https://doi.org/10.1101/gad.14.6.655.
Park HJ, Costa RH, Lau LF, Tyner AL, Raychaudhuri P. Anaphase-promoting complex/cyclosome-CDH1-mediated proteolysis of the forkhead box M1 transcription factor is critical for regulated entry into S phase. Mol Cell Biol. 2008;28:5162–71. https://doi.org/10.1128/MCB.00387-08.
Laoukili J, Alvarez-Fernandez M, Stahl M, Medema RH. FoxM1 is degraded at mitotic exit in a Cdh1-dependent manner. Cell Cycle. 2008;7:2720–6. https://doi.org/10.4161/cc.7.17.6580.
Wang X, Arceci A, Bird K, Mills CA, Choudhury R, Kernan JL, Zhou C, Bae-Jump V, Bowers A, Emanuele MJ. VprBP/DCAF1 regulates the degradation and nonproteolytic activation of the cell cycle transcription factor FoxM1. Mol Cell Biol. 2017;37 https://doi.org/10.1128/MCB.00609-16.
Jeffery JM, Kalimutho M, Johansson P, Cardenas DG, Kumar R, Khanna KK. FBXO31 protects against genomic instability by cap** FOXM1 levels at the G2/M transition. Oncogene. 2017;36:1012–22. https://doi.org/10.1038/onc.2016.268.
Kongsema M, Zona S, Karunarathna U, Cabrera E, Man EPS, Yao S, Shibakawa A, Khoo U-S, Medema RH, Freire R, Lam EW-F. RNF168 cooperates with RNF8 to mediate FOXM1 ubiquitination and degradation in breast cancer epirubicin treatment. Oncogene. 2016;5:e252. https://doi.org/10.1038/oncsis.2016.57.
Karunarathna U, Kongsema M, Zona S, Gong C, Cabrera E, Gomes AR, Man EPS, Khongkow P, Tsang JW-H, Khoo U-S, Medema RH, Freire R, Lam EW-F. OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance. Oncogene. 2016;35:1433–44. https://doi.org/10.1038/onc.2015.208.
Wang Y, Zhou X, Xu M, Weng W, Zhang Q, Yang Y, Wei P, Du X. OTUB1-catalyzed deubiquitination of FOXM1 facilitates tumor progression and predicts a poor prognosis in ovarian cancer. Oncotarget. 2016;7:36681–97. https://doi.org/10.18632/oncotarget.9160.
Schimmel J, Eifler K, Sigurethsson JO, Cuijpers SAG, Hendriks IA, Verlaan-de Vries M, Kelstrup CD, Francavilla C, Medema RH, Olsen JV, Vertegaal ACO. Uncovering SUMOylation dynamics during cell-cycle progression reveals FoxM1 as a key mitotic SUMO target protein. Mol Cell. 2014;53:1053–66. https://doi.org/10.1016/j.molcel.2014.02.001.
Wang C-M, Liu R, Wang L, Nascimento L, Brennan VC, Yang W-H. SUMOylation of FOXM1B alters its transcriptional activity on regulation of MiR-200 family and JNK1 in MCF7 human breast cancer cells. Int J Mol Sci. 2014;15:10233–51. https://doi.org/10.3390/ijms150610233.
Myatt SS, Kongsema M, Man CW-Y, Kelly DJ, Gomes AR, Khongkow P, Karunarathna U, Zona S, Langer JK, Dunsby CW, Coombes RC, French PM, Brosens JJ, Lam EW-F. SUMOylation inhibits FOXM1 activity and delays mitotic transition. Oncogene. 2014;33:4316–29. https://doi.org/10.1038/onc.2013.546.
Jaiswal N, John R, Chand V, Nag A. Oncogenic human papillomavirus 16E7 modulates SUMOylation of FoxM1b. Int J Biochem Cell Biol. 2015;58:28–36. https://doi.org/10.1016/j.biocel.2014.11.002.
Lv C, Zhao G, Sun X, Wang P, **e N, Luo J, Tong T. Acetylation of FOXM1 is essential for its transactivation and tumor growth stimulation. Oncotarget. 2016;7 https://doi.org/10.18632/oncotarget.11332.
Cohn O, Feldman M, Weil L, Kublanovsky M, Levy D. Chromatin associated SETD3 negatively regulates VEGF expression. Nat Publ Gr. 2016:1–10. https://doi.org/10.1038/srep37115.
Gartel AL. FOXM1 in Cancer: interactions and vulnerabilities. Cancer Res. 2017;77:3135–9. https://doi.org/10.1158/0008-5472.CAN-16-3566.
Wierstra I, Alves J. Transcription factor FOXM1c is repressed by RB and activated by cyclin D1/Cdk4. Biol Chem. 2006;387:949–62. https://doi.org/10.1515/BC.2006.119.
Kalinichenko VV, Major ML, Wang X, Petrovic V, Kuechle J, Yoder HM, Dennewitz MB, Shin B, Datta A, Raychaudhuri P, Costa RH. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19 ARF tumor suppressor. Genes Dev. 2004;18:830–50. https://doi.org/10.1101/gad.1200704.1996.
Bhat UG, Jagadeeswaran R, Halasi M, Gartel AL. Nucleophosmin interacts with FOXM1 and modulates the level and localization of FOXM1 in human cancer cells. J Biol Chem. 2011;286:41425–33. https://doi.org/10.1074/jbc.M111.270843.
Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim S-H, Mao P, Kig C, Nardini D, Sobol RW, Chow LML, Kornblum HI, Waclaw R, Beullens M, Nakano I. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells. 2013;31:1051–63. https://doi.org/10.1002/stem.1358.
Sullivan C, Liu Y, Shen J, Curtis A, Newman C, Hock JM, Li X. Novel interactions between FOXM1 and CDC25A regulate the cell cycle. PLoS One. 2012;7:e51277. https://doi.org/10.1371/journal.pone.0051277.
Yang L, He K, Yan S, Yang Y, Gao X, Zhang M, **a Z, Huang Z, Huang S, Zhang N. Metadherin/astrocyte elevated gene-1 positively regulates the stability and function of forkhead box M1 during tumorigenesis. Neuro-Oncology. 2017;19:352–63. https://doi.org/10.1093/neuonc/now229.
Xu M-D, Wang Y, Weng W, Wei P, Qi P, Zhang Q, Tan C, Ni S-J, Dong L, Yang Y, Lin W, Xu Q, Huang D, Huang Z, Ma Y, Zhang W, Sheng W, Du X. A positive feedback loop of lncRNA-PVT1 and FOXM1 facilitates gastric Cancer growth and invasion. Clin Cancer Res. 2017;23:2071–80. https://doi.org/10.1158/1078-0432.CCR-16-0742.
Mónica AF, Medema RH. Novel functions of FoxM1: from molecular mechanisms to cancer therapy. Front Oncol. 2013;3:30. https://doi.org/10.3389/fonc.2013.00030.
Halasi M, Gartel AL. Targeting FOXM1 in cancer. Biochem Pharmacol. 2013;85:644–52. https://doi.org/10.1016/j.bcp.2012.10.013.
Wierstra I. FOXM1 (Forkhead box M1) in tumorigenesis. Overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. 1st ed: Elsevier Inc; 2013. https://doi.org/10.1016/B978-0-12-407190-2.00016-2.
Petrovic V, Costa RH, Lau LF, Raychaudhuri P, Tyner AL. Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin. Cancer Biol Ther. 2010;9:1008–16. https://doi.org/10.4161/cbt.9.12.11710.
Dong GZ, Ji HJ, Lee YI, Lee SY, Zhao HY, Jeon R, Lee HJ, Ryu JH. Diarylheptanoids suppress proliferation of pancreatic cancer PANC-1 cells through modulating shh-Gli-FoxM1 pathway. Arch Pharm Res. 2017;40:509–17. https://doi.org/10.1007/s12272-017-0905-2.
Gartel AL. Thiazole antibiotics Siomycin a and Thiostrepton inhibit the transcriptional activity of FOXM1. Front Oncol. 2013;3:150. https://doi.org/10.3389/fonc.2013.00150.
Hegde NS, Sanders DA, Rodriguez R, Balasubramanian S. The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat Chem. 2011;3:829. https://doi.org/10.1038/nchem.1114.
Sun L, Ren X, Wang IC, Pradhan A, Zhang Y, Flood HM, Han B, Whitsett JA, Kalin TV, Kalinichenko VV. The FOXM1 inhibitor RCM-1 suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice. Sci Signal. 2017;10:eaai8583. https://doi.org/10.1126/scisignal.aai8583.
Halasi M, Hitchinson B, Shah BN, Váraljai R, Khan I, Benevolenskaya EV, Gaponenko V, Arbiser JL, Gartel AL. Honokiol is a FOXM1 antagonist. Cell Death Dis. 2018;9:84. https://doi.org/10.1038/s41419-017-0156-7.
Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904–12. https://doi.org/10.1038/onc.2008.271.
Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73. https://doi.org/10.1186/s12916-016-0623-5.
Prots I, Skapenko A, Lipsky PE, Schulzekoops H. Analysis of the transcriptional Program of develo** induced regulatory T cells. PLoS One. 2011;6:e16913. https://doi.org/10.1371/journal.pone.0016913.
M.C. Gage, N. Bécares, R. Louie, K.E. Waddington, Y. Zhang, T.H. Tittanegro, S. Rodr’\iguez-Lorenzo, A. Jathanna, B. Pourcet, O.M. Pello, J. V la Rosa, A. Castrillo, I. Pineda-Torra, Disrupting LXRα phosphorylation promotes FoxM1 expression and modulates atherosclerosis by inducing macrophage proliferation, Proc Natl Acad Sci (2018). doi:https://doi.org/10.1073/pnas.1721245115.
Yokomine K, Senju S, Nakatsura T, Irie A, Hayashida Y, Ikuta Y, Harao M, Imai K, Baba H, Iwase H. The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy, Int. J Cancer J Int Du Cancer. 2010;126:2153–63. https://doi.org/10.1002/ijc.24836.
Teh MT. Wins Molecule of the Year 2010. 2010. http://ismcbbpr.synthasite.com/molyearnews/foxm1-wins-molecule-of-the-year-2010.
Gormally MV, Dexheimer TS, Marsico G, Sanders DA, Lowe C, Matak-Vinkovic D, Michael S, Jadhav A, Rai G, Maloney DJ, Simeonov A, Balasubramanian S. Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. Nat Commun. 2014;5:5165. https://doi.org/10.1038/ncomms6165.
Gartel AL. FoxM1 inhibitors as potential anticancer drugs. Expert Opin Ther Targets. 2008;12:663–5. https://doi.org/10.1517/14728222.12.6.663.
Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A, Amati B. Genomic targets of the human c-Myc protein. Genes Dev. 2003;17:1115–29. https://doi.org/10.1101/gad.1067003.
Pan H, Zhu Y, Wei W, Shao S, Rui X. Transcription factor FoxM1 is the downstream target of c-Myc and contributes to the development of prostate cancer. World J Surg Oncol. 2018;16:59. https://doi.org/10.1186/s12957-018-1352-3.
McGovern UB, Francis RE, Peck B, Guest SK, Wang J, Myatt SS, Krol J, Kwok JM-M, Polychronis A, Coombes RC, Lam EW-F. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther. 2009;8:582–91. https://doi.org/10.1158/1535-7163.MCT-08-0805.
Pandit B, Halasi M, Gartel AL. p53 negatively regulates expression of FoxM1. Cell Cycle. 2009;8:3425–7. https://doi.org/10.4161/cc.8.20.9628.
Zhang T, Ma G, Zhang Y, Huo H, Zhao Y. miR-216b inhibits glioma cell migration and invasion through suppression of FoxM1. Oncol Rep. 2017;38:1751–9. https://doi.org/10.3892/or.2017.5824.
Sun M, Wang X, Tu C, Wang S, Qu J, **ao S. microRNA-216b inhibits cell proliferation and migration in human melanoma by targeting FOXM1 in vitro and in vivo. Cell Biol Int. 2017; https://doi.org/10.1002/cbin.10754.
Zheng W-W, Zhou J, Zhang C-H, Liu X-S. MicroRNA-216b is downregulated in hepatocellular carcinoma and inhibits HepG2 cell growth by targeting Forkhead box protein M1. Eur Rev Med Pharmacol Sci. 2016;20:2541–50.
Hou XW, Sun X, Yu Y, Zhao HM, Yang ZJ, Wang X, Cao XC. miR-361-5p suppresses lung cancer cell lines progression by targeting FOXM1. Neoplasma. 2017;64:526–34. https://doi.org/10.4149/neo_2017_406.
Weng W, Okugawa Y, Toden S, Toiyama Y, Kusunoki M, Goel A. FOXM1 and FOXQ1 are promising prognostic biomarkers and novel targets of tumor-suppressive miR-342 in human colorectal Cancer. Clin Cancer Res. 2016;22:4947–57. https://doi.org/10.1158/1078-0432.CCR-16-0360.
Tan X, Fu Y, Chen L, Lee W, Lai Y, Rezaei K, Tabbara S, Latham P, Teal CB, Man Y-G, Siegel RS, Brem RF, Fu SW. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer. Oncotarget. 2016;7:293–307. https://doi.org/10.18632/oncotarget.6344.
Y. Ke, W. Zhao, J. **ong, R. Cao, miR-149 inhibits non-small-cell lung Cancer cells EMT by targeting FOXM1., Biochem Res Int 2013 (2013) 506731. doi:https://doi.org/10.1155/2013/506731.
Ma N, Zhang W, Qiao C, Luo H, Zhang X, Liu D, Zang S, Zhang L, Bai J. The tumor suppressive role of MiRNA-509-5p by targeting FOXM1 in non-small cell lung Cancer. Cell Physiol Biochem. 2016;38:1435–46. https://doi.org/10.1159/000443086.
Yuan F, Wang W. MicroRNA-802 suppresses breast cancer proliferation through downregulation of FoxM1. Mol Med Rep. 2015;12:4647–51. https://doi.org/10.3892/mmr.2015.3921.
Xu X, Chen W, Miao R, Zhou Y, Wang Z, Zhang L, Wan Y, Dong Y, Qu K, Liu C. miR-34a induces cellular senescence via modulation of telomerase activity in human hepatocellular carcinoma by targeting FoxM1/c-Myc pathway. Oncotarget. 2015;6:3988–4004. https://doi.org/10.18632/oncotarget.2905.
Duan N, Hu X, Yang X, Cheng H, Zhang W. MicroRNA-370 directly targets FOXM1 to inhibit cell growth and metastasis in osteosarcoma cells. Int J Clin Exp Pathol. 2015;8:10250–60.
Yungang W, **aoyu L, Pang T, Wenming L, Pan X. miR-370 targeted FoxM1 functions as a tumor suppressor in laryngeal squamous cell carcinoma (LSCC). Biomed Pharmacother. 2014;68:149–54. https://doi.org/10.1016/j.biopha.2013.08.008.
Feng Y, Wang L, Zeng J, Shen L, Liang X, Yu H, Liu S, Liu Z, Sun Y, Li W, Chen C, Jia J. FoxM1 is overexpressed in helicobacter pylori-induced gastric carcinogenesis and is negatively regulated by miR-370. Mol Cancer Res. 2013;11:834–44. https://doi.org/10.1158/1541-7786.MCR-13-0007.
Huang X, Qin J, Lu S. Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1. Int J Clin Exp Pathol. 2015;8:1515–24.
Wan L-Y, Deng J, **ang X-J, Zhang L, Yu F, Chen J, Sun Z, Feng M, **ong J-P. miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1. Biochem Biophys Res Commun. 2015;457:125–32. https://doi.org/10.1016/j.bbrc.2014.11.039.
Li T, Ma J, Han X, Jia Y, Yuan H, Shui S, Guo D. MicroRNA-320 enhances Radiosensitivity of glioma through down-regulation of Sirtuin type 1 by directly targeting Forkhead box protein M1. Transl Oncol. 2018;11:205–12. https://doi.org/10.1016/j.tranon.2017.12.008.
Sun Y, Yu X, Bai Q. miR-204 inhibits invasion and epithelial-mesenchymal transition by targeting FOXM1 in esophageal cancer. Int J Clin Exp Pathol. 2015;8:12775–83.
Inoguchi S, Seki N, Chiyomaru T, Ishihara T, Matsushita R, Mataki H, Itesako T, Tatarano S, Yoshino H, Goto Y, Nishikawa R, Nakagawa M, Enokida H. Tumour-suppressive microRNA-24-1 inhibits cancer cell proliferation through targeting FOXM1 in bladder cancer. FEBS Lett. 2014;588:3170–9. https://doi.org/10.1016/j.febslet.2014.06.058.
Park TJ, Kim JY, Oh SP, Kang SY, Kim BW, Wang HJ, Song KY, Kim HC, Lim IK. TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1-Forkhead box M1 regulation loop. Hepatology. 2008;47:1533–43. https://doi.org/10.1002/hep.22212.
Li L, Pan D, Chen H, Zhang L, **e W. F-box protein FBXL2 inhibits gastric cancer proliferation by ubiquitin-mediated degradation of forkhead box M1. FEBS Lett. 2016;590:445–52. https://doi.org/10.1002/1873-3468.12071.
Liu J, Guo S, Li Q, Yang L, **a Z, Zhang L, Huang Z, Zhang N. Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1. J Neuro-Oncol. 2013;111:245–55. https://doi.org/10.1007/s11060-012-1018-x.
Kruiswijk F, Hasenfuss SC, Sivapatham R, Baar MP, Putavet D, Naipal KAT, van den Broek NJF, Kruit W, van der Spek PJ, van Gent DC, Brenkman AB, Campisi J, Burgering BMT, Hoeijmakers JHJ, de Keizer PLJ. Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling. Oncogene. 2016;35:2166–77. https://doi.org/10.1038/onc.2015.282.
Halasi M, Varaljai R, Benevolenskaya E, Gartel AL. A novel function of molecular chaperone HSP70: SUPPRESSION OF ONCOGENIC FOXM1 AFTER PROTEOTOXIC STRESS. J Biol Chem. 2016;291:142–8. https://doi.org/10.1074/jbc.M115.678227.
**ang Q, Tan G, Jiang X, Wu K, Tan W, Tan Y. Suppression of FOXM1 transcriptional activities via a single-stranded DNA aptamer generated by SELEX. Sci Rep. 2017;7:45377. https://doi.org/10.1038/srep45377.
Bi Z, Liu W, Ding R, Wu Y, Dou R, Zhang W, Xue Y, Liu X, **ong L, Guo Z. A novel peptide, 9R-P201, strongly inhibits the viability, proliferation and migration of liver cancer HepG2 cells and induces apoptosis by down-regulation of FoxM1 expression. Eur J Pharmacol. 2016;796:175–89. https://doi.org/10.1016/j.ejphar.2016.12.029.
Acknowledgements
We apologize to those colleagues whose work has not been cited due to space limitation.
Funding
This work was supported by the National Natural Science Foundation of China (No. 81773141, to C. Hu) and Basic and Frontier Research Project of Chongqing, Science and Technology Commission (No. cstc2016jcyjA1930, to C. Hu).
Author information
Authors and Affiliations
Contributions
G-BL, X-ZL, SZ, CL, S-MY, LY, C-JH, and J-YB were involved in the conception, design and drafting of the manuscript. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interest.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Liao, GB., Li, XZ., Zeng, S. et al. Regulation of the master regulator FOXM1 in cancer. Cell Commun Signal 16, 57 (2018). https://doi.org/10.1186/s12964-018-0266-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12964-018-0266-6